Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Access to medicines and treatment news

Show

From To
Natco Pharma ties up with Gilead on hepatitis C drugs

Natco, a mid-sized player in India's crowded pharmaceutical industry, is the latest generic drugmaker to team up with Gilead on Sovaldi, having previously attempted to block the U.S. firm from getting a patent for the breakthrough drug in India in the hope of producing a cheaper version on its own. In September, Gilead announced similar licensing deals with seven other generic drugmakers.

Published
04 March 2015
From
Reuters
HIV and LGTB NGOs and other concerned actors across Europe call for futher action on pre-exposure prophylaxis

The European AIDS Treatment Group (EATG), Europe’s network of HIV activists, and  AIDES, a leading French NGO in the fight against AIDS and viral hepatitis, backed by 81 European HIV LGBT civil society organisations and concerned actors, issued an urgent HIV Prevention Manifesto today. We demand that pre-exposure prophylaxis for HIV (PrEP) is made available as soon as possible within the European Union, and that Gilead, the company that makes the PrEP medicine Truvada®, submits an application to the European Medicines Agency (EMA) for a change of indication so that its use to prevent HIV can be approved.

Published
25 February 2015
From
EATG
Merck places children's HIV drug in shared non-profit patent pool

U.S. drugmaker Merck & Co has contributed an HIV medicine for children to an international shared patent pool in a move that should speed the development of cheap pediatric formulations for use in poor countries.

Published
24 February 2015
From
Reuters
amfAR Report Examines Controversial Pricing of Hepatitis C Treatment

The new amfAR report, titled “Hepatitis C and Drug Pricing: The Need for a Better Balance,” urges structural changes that alter the pricing incentives for pharmaceutical companies in such a way that they cannot charge exorbitant prices for their products, however effective they may be.

Published
19 February 2015
From
amfAR
The Drug That Is Bankrupting America

With a rational U.S. drug pricing system, private investors would expect to earn a reasonable multiple of their R&D for a highly successful drug, perhaps even 5 to 10 times the R&D outlays, in order to reflect the long time horizons and high uncertainties surrounding drug development. Yet at a treatment course of $84,000, the multiple for Sovaldi looks to be around 40 times or more.

Published
18 February 2015
From
Huffington Post
Migrant primary care charge proposals shelved... for now...

Migrant rights campaigners can celebrate this week. It seems that ongoing lobbying has led the Department of Health to kick plans for new primary care charges for migrants into the long grass... Now we need to make sure they don't return in the autumn to haunt us.

Published
16 February 2015
From
Migrants' Rights Network
Dept of Health - Charging for primary care de-prioritised and postponed

At a meeting yesterday with the Visitor and Migrant NHS Cost Recovery Programme, the Department of Health announced that plans to extend and amend charging for visitors and migrants for primary care has been de-prioritised and will be subject to public consultation in autumn 2015.

Published
13 February 2015
From
Migrants Rights Network
UNITAID: 2015 Hepatitis C medicines technology and market landscape

This report takes stock of a rapidly changing market, where new products have the potential to become “blockbusters” almost overnight – but also risk becoming quickly outdated due to superior products entering the market.

Published
13 February 2015
From
UNITAID
Activists Claim India's Free HIV/AIDS Program Is In 'Shambles'

India has run out of critical supplies under its state-run HIV/AIDS program, activists say, leaving tens of thousands of infected patients without access to life-saving drugs. There are also shortages of condoms and needles.

Published
13 February 2015
From
Wall Street Journal
Gilead agrees 41,000 euro hep-C drug price for 12 week treatment in Germany

Drugmaker Gilead has agreed on a price for its hepatitis C drug Sovaldi of 41,000 euros ($46,625) for a 12-week treatment for Germany's statutory medical insurers, the GKV association of Germany's statutory medical insurers said.

Published
13 February 2015
From
Reuters
← First12345...87Next →

Filter by country